Despite the success of antiretroviral therapy (ART), there is currently no HIV cure and
treatment is life long. HIV persists during ART due to long-lived and proliferating latently …

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

The response to coronavirus disease 2019 (COVID-19) appears no different. We are not
aware of any gender analysis of the outbreak by global health institutions or governments in …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

Long-lasting, latently infected resting CD4+ T cells are the greatest obstacle to obtaining a
cure for HIV infection, as these cells can persist despite decades of treatment with …

The main barrier to HIV cure is a persistent reservoir of latently infected CD4+ T cells
harboring replication-competent provirus that fuels rebound viremia upon antiretroviral …

Infectious diseases are the leading cause of mortality worldwide, with viruses in particular
making global impact on healthcare and socioeconomic development. In addition, the rapid …

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

Pharmacologically-induced activation of replication competent proviruses from latency in the
presence of antiretroviral treatment (ART) has been proposed as a step towards curing HIV …

In people living with HIV (PLWH) who are failing or unable to access combination
antiretroviral therapy (cART), monocytes and macrophages are important drivers of …